Cerebrolysin

Dr. Pradeep Albert discusses cerebrolysin as a neuropeptide growth factor containing three growth factors. He reports running a clinical trial using cerebrolysin on patients with recent ischemic strokes, noting it addresses the stroke penumbra where no other treatment exists. For healthy aging individuals with ischemia, he recommends cerebrolysin IV infusion for cognitive improvement. Cautions that fast IV infusion can cause heart arrhythmia in patients with heart conditions — must be under physician guidance. He combines cerebrolysin with intranasal mesenchymal stem cells and intrathecal administration for a three-pronged approach.

The speaker presents a comprehensive five-peptide stack for age reversal: GHK-Cu (2 mg/day foundation), MOTS-c (mitochondrial energy), Epitalon (telomere support and sleep, cycled 20 days on/4 months off), Cerebrolysin (cognitive/brain repair), and BPC-157 (systemic repair). Each peptide is assigned a specific pillar: genetic expression, cellular energy, sleep systems, brain function, and systemic repair respectively. The stack is described as comprehensive, synergistic, and addressing all core pillars of aging.

The combination of GHK-Cu and Cerebrolysin is described as synergistically enhancing synaptic plasticity, memory, and recovery from traumatic brain injuries (TBIs). GHK-Cu provides neuronal protection while Cerebrolysin enhances neurotrophic signaling. Together they are framed as upgrading the 'hardware' of the mind.

The speaker explicitly considers and then rejects Phenylpiracetam in favor of Cerebrolysin for the cognitive component of the stack. The rationale is that Cerebrolysin is not a synthetic peptide and instead provides a natural mixture of neurotrophic factors. No clinical evidence is cited for this preference.

The speaker briefly considers Phenylpiracetam Hydrazide as a cognitive agent but explicitly rejects it in favor of Cerebrolysin. The stated reason is that Cerebrolysin is not a synthetic peptide and instead consists of natural neurotrophic factors. This represents a safety/preference consideration within the cognitive enhancement component of the stack.

The speaker presents a comprehensive five-component age reversal stack: GHK-Cu (genetic expression/tissue building), MOTS-c (cellular energy/mitochondrial biogenesis), Epitalon (telomere support/sleep), BPC-157 (systemic repair), and Cerebrolysin (brain function). Each peptide is assigned a specific pillar of aging it addresses. The stack is described as 'comprehensive, synergistic, and brutally effective,' targeting genetic expression, cellular energy, sleep systems, systemic repair, and brain function.

Combining GHK-Cu's neuroprotective properties with Cerebrolysin's neurotrophic factors is claimed to enhance synaptic plasticity, improve memory, and support recovery from brain injuries including TBIs. The speaker frames this combination as 'upgrading the hardware of your mind.' No specific dosages for this combination are provided.

Cerebrolysin is recommended as the cognitive component of the stack, described as a mixture of neurotrophic factors rather than a synthetic peptide. The speaker uses the metaphor of 'concentrated fertilizer for growth and repair' for the brain. It is preferred over Phenylpiracetam (a synthetic nootropic) for its natural neurotrophic factor composition.

Clinician describes Cerebrolysin as a brain-and-nerve peptide delivering a complex of neurotrophic factors (BDNF, NGF, GDNF, CNTF). Reported mechanisms: enhances neuronal survival and differentiation, increases synaptogenesis, is anti-excitotoxic, supports the blood-brain barrier, and lowers TNF-alpha. Framed as neuroprotective and neurorestorative for both central and peripheral nerve.

The clinician offers a broad expert opinion that peptides as a class demonstrate powerful nerve-treating and neuroprotective abilities, though he acknowledges they do not help every condition. This claim is based on his clinical experience rather than cited studies. No specific mechanism of action is elaborated upon in this excerpt.

The speaker explains that Cerebrolysin's approximately 50-peptide composition creates an insurmountable regulatory obstacle in the United States, as each individual peptide would require its own separate FDA authorization process. This is estimated to take 50–70 years, making commercial approval economically and practically unviable. As a result, patients seeking this treatment must travel abroad.

Cerebrolysin is described as a mixture of approximately 50 different peptides that functions to repair neurons. It is widely used in Austria as a standard-of-care treatment for traumatic brain injury and stroke, administered at high doses in hospital settings. The speaker notes it is not available in the United States due to regulatory barriers.

Two clinicians report Cerebrolysin and ARA-290 as primary peptides for nerve pain, used in concert with BPC-157 and thymosin beta-4 (TB-500); rationale is reduction of neuroinflammation. Includes a patient anecdote of an acute arm movement disorder resolving after intramuscular ARA-290 and Cerebrolysin, with no recurrence.

The case highlights intramuscular (IM) injection as a practical alternative administration route when intravenous (IV) access is difficult or not feasible. Both ARA-290 and Cerebrolysin were administered intramuscularly in this instance. No dosage, volume, or injection site details were provided.

A college student presenting with involuntary arm movements received intramuscular injections of both ARA-290 and Cerebrolysin. According to the clinician's account, her symptoms resolved rapidly — within the time it took the doctor to see another patient and return. No specific dosages were mentioned for either compound.

Cross-sectional survey of Romanian healthcare students found that the likelihood of using synthetic nootropics, grouped as piracetam/cerebrolysin, rose 1.86x (OR 1.86, p=0.021) as university education progressed. This is usage-prevalence data only. Cerebrolysin is named incidentally inside a combined nootropic category, so the study carries no information on cerebrolysin dosing, route, efficacy, or safety and does not alter its evidence position.

Prospective single-blind controlled cohort (n=340) from Thailand. Cerebrolysin 30mL/day IV for 10 days in moderate TBI with nonoperative ICH. Significant improvement in CRS-R scores at discharge (20.3±2.7 vs 16.4±2.1, p=0.013), higher Barthel Index, lower mRS, improved 6-month survival (59.4% vs 27.8%, p<0.001). No increased adverse events. Limitation: non-randomized, single-blind.

Longevity medicine physician discusses Cerebrolysin as standard TBI/stroke treatment in Austria. Notes it's a mix of ~50 peptides that repairs neurons, unavailable in US due to regulatory burden of approving each peptide individually. Highlights gap between international and US availability.

Reconstitution protocol for 60mg lyophilized Cerebrolysin: Add 3.0 mL bacteriostatic water (inject slowly down vial wall, gently swirl, do not shake) → 20 mg/mL concentration. SubQ injection at 45-90°. Titration: Week 1: 20mg/day (100 units/1.0mL once daily); Week 2: 24mg/day (60 units AM + 60 units PM); Week 3: 28mg/day (70u AM + 70u PM); Week 4+: 32mg/day (80u AM + 80u PM). Split doses >100 units into AM/PM at different sites. Cycle: 8-12 weeks (optional 16). Insulin syringe: 1 unit = 0.01mL = 200mcg. Storage post-reconstitution: 2-8°C, use within 7 days, protect from light, do not freeze. Lyophilized vials stored at ≤25°C.

EliteBioGenix sells Cerebrolysin as lyophilized powder in 50mg and 60mg vials. Storage: 2-8°C or -20°C, protect from light, avoid repeated freeze-thaw. No reconstitution instructions provided on product page. In-vitro research concentrations referenced: 2.5-50 µg/mL (cell culture). Product labeled for in-vitro research/laboratory use only. No human dosing, reconstitution ratios, or injection route guidance included.

Cerebrolysin is a complex neuropeptide mixture (not a single peptide) derived from enzymatic hydrolysis of porcine brain tissue. Composition: ~75% free L-amino acids + ~25% low-MW neuropeptides (BDNF, NGF, CNTF, GDNF fragments). Crosses BBB due to <10kDa molecular weight. Approved in 44+ countries (EU, Asia) for stroke/AD/TBI — NOT FDA approved. Benefits: neuroprotection, neurogenesis, BDNF upregulation, synaptic regeneration, dendritic density, anti-inflammatory, antioxidant, mitochondrial energy optimization. Clinical evidence: meta-analysis of 9 RCTs for stroke recovery (PMID 29248999); 6 RCTs for Alzheimer's (PMID 21679156, effect size comparable to cholinesterase inhibitors but Cochrane quality rating = very low); 2025 review of 10 TBI studies (1900+ patients). Dosage: 5mL/day (cognitive support/biohacking), 10-20mL/day (neurological recovery). Cycle: 10-20 days on, then off. ROA: IV infusion (20-60 min slow drip) or IM. Pre-made solution — no reconstitution needed. WARNINGS: porcine-derived (contraindicated in pork allergy, anaphylaxis risk), rare seizures in predisposed individuals, severe hypotension with rapid IV infusion.